liveBook · Manning

IND-enabling studies

As explained in Build AI Drug Discovery Pipelines

An IND-enabling study is a preclinical study package generated to support an investigational new drug application and first-in-human testing.

IND-enabling studies are preclinical investigations that support an investigational new drug application and first-in-human testing. They connect an optimized lead to clinical-candidate readiness through experimental safety, pharmacology, and efficacy evidence. section 13.3.1

A practical package can include:

  • Confirming potency and cellular activity across multiple assay formats. section 13.3.1
  • Profiling selectivity experimentally against broad target panels rather than relying only on computational predictions. section 13.3.1
  • Comparing predicted and measured solubility, permeability, and metabolic stability. section 13.3.1
  • Testing dose-dependent efficacy in an animal disease model. section 13.3.1

Rentosertib program

INS018_055 completed standard IND-enabling studies in nine months. Experimental work confirmed TNIK potency, cellular antifibrotic effects, adequate ADMET properties, and dose-dependent efficacy in pulmonary fibrosis, while revealing off-target kinases missed computationally. section 13.3.1

Figure 13.7 The four stages of the rentosertib program. Multi-omics data and literature flow through PandaOmics to a scored target list; Chemistry42 generates and optimizes candidates against a multi-objective reward; experimental readouts feed back to refine the models; clinical development follows. Sections 13.3.1 through 13.3.4 walk through each stage.

Use the four-stage program figure to place IND-enabling studies within the transition from AI-assisted discovery and lead optimization to clinical development. section 13.3.1

How Build AI Drug Discovery Pipelines covers it

How deep it goes
Details potency, selectivity, ADMET, and animal efficacy validation while showing that computational predictions require experimental confirmation.
Examples
Uses INS018_055, TNIK assays, 430-kinase profiling, ADMET measurements, and a bleomycin-induced pulmonary fibrosis model.
What you can do after
Evaluate candidate readiness by integrating experimental potency, selectivity, ADMET, pharmacokinetic, and efficacy results.
How it connects
Links preclinical validation with pharmacokinetics, ADMET, selectivity profiling, efficacy studies, and clinical development.

This explainer was generated by Manning's knowledge graph from the text of Build AI Drug Discovery Pipelines. The section links point to the parts of the book it draws on.